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Introduction
Acquired hemophilia A (AHA), a rare bleeding disorder 
triggered by autoantibodies against factor VIII (FVIII), occurs 
without a family history of hemophilia.1 Bleeding is usually 
mucocutaneous, soft tissue, or gastrointestinal, and is often 
severe or even life threatening. There is a reported mortality 
rate of 9.7%–33%.2 AHA invariably causes a prolonged acti-
vated partial thromboplastin time (APTT), and the labora-
tory diagnosis is confirmed by demonstrating a reduced FVIII 
level along with a detectable FVIII inhibitor.1 Up to 85% of 
affected individuals are older adults (.60 years) of either sex.1 
To date, the underlying causes of AHA are still under debate. 
In more than 50% of AHA cases, FVIII autoantibodies are 
present in patients without any relevant concomitant diseases. 
The remaining cases may be associated with autoimmune 
diseases, the postpartum period, infections, vaccinations, 
underlying hematologic diseases, or solid cancer.3 Moreover, 
an analysis of literature data showed several cases of drug-
induced anti-FVIII autoantibodies, highlighting this finding 
as one of the most relevant causes of AHA.4
Recently, some cases of AHA associated with antiplate-
let drug such as clopidogrel5,6 and vitamin K antagonist, like 
warfarin,7–10 have been reported. This makes the diagnosis of 
drug-associated autoantibodies against FVIII a complicated 
challenge, since the sudden onset of bleeding might be erro-
neously attributed to these drugs. Clopidogrel, prasugrel, 
or ticagrelor, plus aspirin, is the most commonly used treat-
ment for patients with acute coronary syndrome: the so-called 
dual antiplatelet therapy (DAPT).11 Ticagrelor is an orally 
administered direct-acting P2Y12 receptor antagonist that is 
not a prodrug and does not require metabolic activation for 
antiplatelet activity, unlike clopidogrel and prasugrel, that 
binds irreversibly to the receptor for the life of the platelet.11 
Pharmacodynamic studies have demonstrated that ticagrelor 
has a faster onset and inhibits platelet aggregation more strongly 
than does clopidogrel. These properties may well contribute to 
reduced rates of thrombotic outcomes compared to clopidogrel, 
as demonstrated in a phase III clinical trial (PLATO trial).12 
Ticagrelor represents an advancement in P2Y12 receptor inhi-
bition therapy, and no distinctive adverse effects, other than 
bleeding, have been reported for this new chemical entity.
This report describes a patient, who has given consent 
for publication of all information about his clinical case, with 
AHA associated with ticagrelor therapy who showed complete 
remission after steroid and cyclophosphamide administration, 
in spite of DAPT continuation.
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case report
A 52-year-old man, treated with acetylsalicylic acid (ASA) 
100 mg/day and ticagrelor 180 mg/day (DAPT) for recent 
percutaneous transluminal coronary angioplasty with medi-
cated coronary stents, arrived complaining of right leg pain due 
to a relevant hemorrhagic effusion.
Our patient had severe anemia (Hb 6.9 g/dL), prolonged 
APTT of 80 seconds, and normal prothrombin time and 
platelet levels. The mixing test showed no normalization of 
the prolonged APTT after incubation with severe evident 
FVIII deficiency (1.1%), due to a detectable FVIII inhibi-
tor (6.72 Bethesda units [BU]) confirming the diagnosis of 
AHA. Extensive radiological/hematological examinations, ie, 
computed tomography of the chest and abdomen with contrast 
medium, laboratory testing for antinuclear antibodies, anti-
DNA antibodies, antiphospholipid antibodies, autoantibod-
ies to extractable nuclear antigens, antineutrophil cytoplasmic 
antibodies, C- and S-reactive proteins, activated protein C 
resistance, and serum immunoglobulin tests were uneventful 
for any underlying disorders, such as connective tissue disor-
ders, lymphoproliferative disease, or inflammatory bowel dis-
eases. On the basis of the AHA diagnosis and in line with the 
standard guidelines for its management, prednisone at 100 mg 
and cyclophosphamide at 90 mg were administered daily.
In the present case, skin, muscle, and soft tissue bleeding, 
and APTT prolongation developed within one month after 
ticagrelor had been added to the ASA treatment, while APTT 
had been repeatedly normal before taking this drug. The diag-
nosis was made one month later when the patient arrived to 
our attention after we had dosed an FVIII inhibitor titer of 
6.72 BU/mL. Because of the high risk of stent thrombosis, 
ticagrelor and ASA therapy was continued and treatment with 
prednisone at 100 mg and cyclophosphamide at 90 mg/day 
was promptly started. Following stabilization of the bleeding, 
the immunosuppressive therapy was continued until such time 
as there was eradication of the inhibitor.
After 10 days, APTT dropped from 107 to 49 seconds, 
the patient’s FVIII levels gradually normalized over the fol-
lowing few weeks, and the inhibitor titer was negative. There-
fore, the dosage of cyclophosphamide and prednisone was 
gradually reduced according to the inhibitor titer and the 
FVIII level, but the ticagrelor therapy was not stopped.
The patient was continuously monitored and his FVIII 
levels remained in the normal range. He was given DAPT 
antiplatelet therapy for one year as prescribed by his cardiolo-
gist because of the high risk of stent thrombosis, even though 
ticagrelor had most probably induced the disease.
discussion
According to The European Acquired Haemophilia Regis-
try (EACH2), AHA may be idiopathic even if an under-
lying disorder is identified in about 50% of the patients.13 
Although the drug-induced anti-FVIII antibodies have 
been reported to account for only 3%4 of AHA, the real 
incidence could be underestimated. Moreover, drugs such 
as clopidogrel or warfarin might well mask the correct diag-
nosis of AHA.5–10 Therefore, some authors suggest that for 
elderly patients on clopidogrel or warfarin therapy presenting 
with unusual/unexplained bleeding, not only the treatment 
but also the possibility of AHA should be carefully inves-
tigated.7 Ticagrelor, the first reversible oral P2Y12 receptor 
antagonist, provides faster, greater, and more consistent ade-
nosine diphosphate receptor inhibition, thus becoming an 
accepted option in several clinical situations, such as unstable 
angina, non-ST-segment elevation acute coronary syndrome, 
and percutaneous coronary intervention.11,14,15
In this case, we report a patient diagnosed as having 
developed ticagrelor-associated AHA. Even though, to the 
best of our knowledge, no other such cases have been reported, 
our hypothesis is supported by several factors.
One important point is that the patient developed a severe 
bleeding disorder associated with a significant blood titer of an 
inhibitor against FVIII one month after ticagrelor had been 
added to ASA therapy and after repeatedly dosing a normal 
APTT. The temporal relationship of the administration of the 
drug and the onset of the illness, the prompt clinical and labo-
ratory response to corticosteroids, and the exclusion of causes 
other than drugs or confounding factors are in agreement with 
our hypothesis.
Ticagrelor therapy was not suspended nor was it changed 
for other similar drugs such as clopidogrel. First, the patient’s 
critical clinical situation made it unadvisable to change the 
dosage or interrupt the drug. Second, over time, the immuno-
suppressive therapy controlled the anti-FVIII antibodies. 
Third, clopidogrel may also induce AHA.5,6
The Naranjo algorithm16 was used to evaluate the like-
lihood of adverse drug reaction. This questionnaire included 
10 questions that rate adverse drug reactions using a numeric 
score that ranged from −4 to +13. The reaction is considered 
definite if the score is 9 or higher, probable if it is from 5 to 8, 
possible if it is from 1 to 4, and doubtful if it is 0 or less. AHA 
related to ticagrelol was scored as 5. There are previous sim-
ilar conclusive reports on this reaction,5,6 the adverse event 
appeared after the suspected drug had been administered, 
and there were no alternative causes (other than the drug) 
that could have been responsible for the reaction. Moreover, 
the fact that several publications have reported that AHA is 
an adverse event due to drug treatment is noteworthy, and 
recently, some reports have established a link between the 
development of AHA and clopidogrel.5,6 This finding is in 
line with our hypothesis, since both ticagrelor and clopidogrel 
inhibit the P2Y12 receptors even though ticagrelor shows 
properties that distinguish it from clopidogrel.11,14
conclusions
This case report indicates that ticagrelor might trigger AHA, 
even if an idiopathic form cannot be excluded. Although 
ticagrelor and clopidogrel differ from a chemical point of view, 
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they do share the same P2Y12 receptor action and have the 
same adverse effect.5,6 A prompt response to prednisone and 
cyclophosphamide therapy was obtained in our patient, with-
out suspending DAPT therapy.
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